From: HbA1c as a shared treatment goal in type 2 diabetes? A secondary analysis of the DEBATE trial
Parameter | Total (N = 547) | Sample with shared HbA1c goal (n = 287; 52.47%) | Sample with non-shared HbA1c goal (n = 260; 47.53%) | p | Effect size (Cohen’s d) | |
---|---|---|---|---|---|---|
Age T0, mean (SD) | 64.61 (10.63) | 64.48 (10.64) | 64.75 (10.63) | 0.762 | 0.026 | |
Sex, n (%) | women | 255 (46.62) | 145 (50.52) | 110 (42.31) | 0.054 | 0.165 |
men | 292 (53.38) | 142 (49.48) | 150 (57.69) | |||
Education, n (%) | ≤8 years | 352 (64.35) | 178 (62.02) | 174 (66.92) | 0.232 | 0.102 |
> 8 years | 195 (35.65) | 109 (37.98) | 86 (33.08) | |||
Partner status, n (%) | with | 366 (66.91) | 187 (65.16) | 179 (68.85) | 0.360 | 0.078 |
without | 181 (33.09) | 100 (34.84) | 81 (31.15) | |||
HbA1c goal, mean (SD) | 7.46 (0.58) | 7.36 (0.57) | 7.57 (0.56) | < 0.001 | 0.380 | |
HbA1c measured at T0, mean (SD) | 9.10 (1.04) | 9.00 (0.97) | 9.22 (1.10) | 0.018 | 0.204 | |
Difference between measured HbA1c (T0) and HbA1c goal, mean (SD) | 1.64 (1.05) | 1.65 (1.00) | 1.64 (1.11) | 0.964 | 0.004 | |
Insulin treatment T0, n (%) | yes | 332 (60.69) | 164 (57.14) | 168 (64.62) | 0.074 | 0.153 |
no | 215 (39.31) | 123 (42.86) | 92 (35.38) | |||
SDM-Q-9 T0 (n = 9 missing), mean (SD) | 24.40 (14.05) | 24.21 (14.43) | 24.62 (13.62) | 0.736 | 0.029 | |
PACIC T0 (n = 2 missing), mean (SD) | 2.44 (0.84) | 2.47 (0.80) | 2.41 (0.89) | 0.414 | 0.070 | |
PAID T0 (n = 9 missing), mean (SD) | 14.22 (15.02) | 14.25 (14.80) | 14.20 (15.30) | 0.970 | 0.003 | |
EQ-5D-3 L index T0 (n = 3 missing), mean (SD) | 0.67 (0.31) | 0.66 (0.32) | 0.68 (0.31) | 0.470 | 0.062 |